CD163 and non-small cell lung carcinoma: The joint parameters CD8+/CD8+PD-L1+, CD8+/CD68+CD163+, and CD8+PD-L1+/CD68+CD163+ were also potential indicators for predicting PFS in NSCLC patients receiving ICIs.